177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Summary

This phase 1 dose-escalation and dose-expansion study is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) in patients with metastatic castration resistant prostate cancer (mCRPC).

Timeline

Start

2019-07-09

Primary completion

2025-05

Completion

2026-06

Publications

• Kashyap R, Buteau JP, Bressel M, Eifer M, Bollampally N, Jackson P, McIntosh L, Sandhu S, Hofman MS. Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. J Nucl Med. 2025 Aug 1;66(8):1265-1270. doi: 10.2967/jnumed.125.269640.

Drugs

Indications